Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy.
Fuller
Christopher K
CK
Charlson
John A
JA
Dankle
Steven K
SK
Russell
Thomas J
TJ
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab; D001707:Biopsy, Needle; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005153:Facial Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D005500:Follow-Up Studies; D006394:Hemangiosarcoma / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017239:Paclitaxel